Upcoming Inflammation Conference in Boston :...

Upcoming Inflammation Conference in Boston  :

http://www.bostonleaders.com/files/...ation_leaders_forum_2015__agenda_28.11.14.pdf

Invion is Talking about Athsma :

Targeting healing of the airway epithelium: more than a buffer between air and smooth muscle
Geography of the beta 2 receptor in the asthmatic airway
The opportunity to facilitate healing of the moderate to severely deranged epithelium
Study design for therapy targeting the airway; signs, symptoms, cells, and biomarkers
Dr Mitchell Glass, Executive Vice President R&D & Chief Medical Officer, Invion


Invion's biggest competitor in Lupus  is talking about Lupus:

Treatment of Lupus: the physiopathology approach
The sequence: antigen presenting cells, T-cells and B-cells is valid for all auto-immune diseases. Trying to selectively deplete the body from deleterious sub-sets of B-cells led to disappointing results and to an immunosuppressant warning label by regulatory agencies
Targeting of selective auto-reactive T-cells (and therefore sub-sets of B-cells) is possible through the Altered Peptide Ligand approach that allows the modulation of specific sub-sets of T-cells inducing their anergization with consequences toward the respective auto-reactive B-cells.
Additionally, a broader approach involving auto-reactive T-cells and the control of hyperautophagy found in lupus can also lead to their anergization resulting in a depletion of the deleterious auto-reactive B-cells.
Lupuzor a modified 21-mer peptide bearing a T-cell epitope has demonstrated to be able to address both mechanisms with clinically significant results
Dr Robert Zimmer, President & Chief Scientific Officer, Immupharma


Kinda shows priorities for Invion !